

## DAFTAR PUSTAKA

1. Alrabadi, A. *et al.* (2020) 'Evaluation of Voiding Position on Uroflowmetry Parameters and Post Void Residual Urine in Patients With Benign Prostatic Hyperplasia and Healthy Men', *American Journal of Men's Health*, 14(4), pp. 0–5. doi: 10.1177/1557988320938969.
2. Devlin, C. M., Simms, M. S. and Maitland, N. J. (2021) 'Benign prostatic hyperplasia – what do we know?', *BJU International*, 127(4), pp. 389–399. doi: 10.1111/bju.15229.
3. G.Jakse, C. Bouffieux, J. de Leval, R. A. J. (2013) *Benign Prostatic Hyperplasia - Conservative and Operative Management*. 1st edn. Heidelberg: Springer Berlin.
4. Henry, G. H. *et al.* (2018) 'A Cellular Anatomy of the Normal Adult Human Prostate and Prostatic Urethra', *Cell Reports*, 25(12), pp. 3530-3542.e5. doi: 10.1016/j.celrep.2018.11.086.
5. Ikatan Ahli Urologi Indonesia (IAUI) (2021) *Panduan Praktik Klinis Pembesaran Prostat Jinak (Benign Prostatic Hyperplasia/BPH)*.
6. Kemenkes RI (2018) *Riset Kesehatan Dasar*. Jakarta.
7. Lee, S. W. H., Chan, E. M. C. and Lai, Y. K. (2017) 'The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis', *Scientific Reports*, 7(1), pp. 1–10. doi: 10.1038/s41598-017-06628-8.
8. Lerner, L. B. *et al.* (2021) 'Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia: AUA GUIDELINE PART I -



- Initial Work-up and Medical Management’, *Journal of Urology*, 206(4), pp. 806–817. doi: 10.1097/JU.0000000000002183.
9. Lwanga, S. K. and Lemeshow, S. (1991) *Sample Size Determination in Health Studies: A Practical Manual.*, *Journal of the American Statistical Association*. doi: 10.2307/2290547.
  10. Mansbart, F. *et al.* (2022) ‘Efficacy and safety of adrenergic alpha-1 receptor antagonists in older adults: a systematic review and meta-analysis supporting the development of recommendations to reduce potentially inappropriate prescribing’, *BMC Geriatrics*, 22(1). doi: 10.1186/s12877-022-03415-7.
  11. McLaughlin, P. W. *et al.* (2005) ‘Functional anatomy of the prostate: Implications for treatment planning’, *International Journal of Radiation Oncology Biology Physics*, 63(2), pp. 479–491. doi: 10.1016/j.ijrobp.2005.02.036.
  12. Miernik, A. and Gratzke, C. (2020) ‘Current treatment for benign prostatic hyperplasia’, *Deutsches Arzteblatt International*, 117, pp. 843–854. doi: 10.3238/arztebl.2020.0843.
  13. Monoarfa, R. A. and Mochtar, C. A. (2014) ‘Validation of Indonesian Version of Ipps’, *Indonesian Journal of Urology*, 21(1). doi: 10.32421/juri.v21i1.20.
  14. Netter, F. H. (2018) *Atlas of Human Anatomy*. 7th edn. Philadelphia: Saunders Elsevier.
  15. Nugroho, E. A. (2019) ‘A Correlation Study of International Prostate



- Symptom Score (IPSS) and Visual Prostate Symptom Score (VPSS) Study in Benign Prostatic Hyperplasia Cases’, *International Journal of Medicine and Pharmaceutical Sciences*, 9(4), pp. 29–34. doi: 10.24247/ijmpsaug20194.
16. Pramana, I. B. P. *et al.* (2020) ‘The effectiveness of tamsulosin in Benign Prostate Hyperplasia (BPH) patients with Lower Urinary Tract Symptoms (LUTS): a multi-centre cohort retrospective study’, *Indonesia Journal of Biomedical Science*, 14(1), pp. 17–20. doi: 10.15562/ijbs.v14i1.214.
  17. Russo, G. I. *et al.* (2021) ‘Relationship between dietary patterns with benign prostatic hyperplasia and erectile dysfunction: A collaborative review’, *Nutrients*, 13(11), pp. 1–12. doi: 10.3390/nu13114148.
  18. Sasidharan, S. *et al.* (2022) ‘Benign Prostatic Hyperplasia (BPH): A Comprehensive Analysis of the Malaise and Summarizing Possible Management Options through Phytotherapeutic Agents’, *Kesmas*, 17(2), pp. 81–88. doi: 10.21109/kesmas.v17i2.5887.
  19. Scher, H. and Eastham, J. (2018) ‘Benign and malignant diseases of the prostate’, in *Harrison’s principles of internal medicine*. 1st edn. Heidelberg: Springer Berlin, p. 632.
  20. Wang, Y. B. *et al.* (2022) ‘Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study’, *Journal of Translational Medicine*, 20(1), pp. 1–12. doi: 10.1186/s12967-022-03722-y.
  21. Zhou, Z. *et al.* (2019) ‘Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia’, *BMC Urology*, 19(1), pp. 1–12. doi: 10.1186/s12894-019-0446-8.
  22. Manohar CMS., *et al.* Safety and efficacy of tamsulosin, alfuzosin or silodosin as monotherapy for LUTS in BPH-a double-blind randomized trial. *Cent European J Urol*. 2017 Jun 7;70(2):148-53. doi: 10.5173/cej.2017.924
  23. happle CR, Montorsi F, Tammela TLJ, *et al.* Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: Results of an international, randomized, double-blind, placebo- an active-controlled clinical trial rrmormed in europe. *European Urology*. 2011 March;59(3):342-52.



24. Guess HA. Benign prostatic hyperplasia: antecedants and natural history. *Epidemiol Rev.* 1992;14:131-53.
25. Jacobsen SJ, Girman CJ, Guess HA, et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in United States. *Arch Intern Med.* 1995;155:477-81.
26. Kobayashi K, Masumori N, Kato R, et al. Orgasm is preserved regardless of ejaculatory dysfunction with selective 1A-blocker administrasion. *Int J Impot Res.* 2009;21:306-10.
27. Kawabe K, Yoshida M, Homma Y, et al. Silodosin, a new  $\alpha$ 1A-adrenoreceptor- selective antagonist for treating benign prostatic hyperplasa: results of a phase III randomized, placebo-controlled, double-blind study in japanese men. *BJU Int.* 2006;98:1019-24.
28. Miyamae K, Kintani K, Miyamoto K, et al. Early therapeutic benefit of  $\alpha$ 1- blockers-comparison based on patient assessments. *Jpn J Urol Surg.* 2009;22:1541-48.
29. Kobayashi K, Masumori N, Hisause S, et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective 1A-blocker in normal volunteers. *J Sex Med.* 2008; 5:2185-90.
30. Matsumoto S, Hanai T, Saito M, et al. Ejaculatory disorder by silodosin in healthy volunteer. *Jpn J Urol.* 2007;20:1289-93.
31. Pande S, Hazra A, Kundu AK. Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia A randomized controlled trial. *Indian Journal of Pharmacology.* 2014 Nov-Dec;46(6):601-7.

